| HRA008073
(Controlled Access)
|
This study assesses the efficacy of different treatment approaches, such as the use of cadonilimab and anlotinib, by monitoring the patient's response through various cycles of treatment. This includes the use of computed tomography scans to evaluate treatment response. We believe that our study makes a significant contribution to the literature because the case report explores alternative treatment options for pulmonary large cell neuroendocrine carcinoma patients who have shown resistance to traditional programmed death 1 monoclonal antibodies and multiple chemotherapies. The use of cadonilimab and anlotinib in this context is highlighted, suggesting that this combination could be a potential treatment strategy. |
